The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma

被引:23
作者
Wu, Hui-Ta [1 ]
Xie, Cheng-Rong [2 ]
Lv, Jie [2 ]
Qi, He-Qiang [2 ]
Wang, Fei [3 ]
Zhang, Sheng [2 ]
Fang, Qin-Liang [2 ]
Wang, Fu-Qiang [2 ]
Lu, Yu-Yan [2 ]
Yin, Zhen-Yu [2 ]
机构
[1] Xiamen Univ, Zhongshan Hosp, Dept Oncol, Xiamen 361004, Fujian, Peoples R China
[2] Xiamen Univ, Zhongshan Hosp, Dept Hepatobiliary Surg, Fujian Prov Key Lab Chron Liver Dis & Hepatocellu, Xiamen 361004, Fujian, Peoples R China
[3] Mengchao Hepatobiliary Hosp, United Innovat Mengchao Hepatobiliary Technol Key, Fuzhou 350025, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
SIGNALING AXIS; GROWTH; IDENTIFICATION; INVASION; PATHWAY; KINASE; CELLS; LIVER; PROLIFERATION; RECURRENCE;
D O I
10.1038/s41374-018-0062-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Downregulation of deleted in liver cancer 1 (DLC1) is associated with poor prognosis of various cancers, but its functional mechanisms in hepatocellular carcinoma (HCC) remains unclear. In the present study, we investigated the roles of DLC1 in tumor progression and autophagy of HCC. We found that DLC1 was frequently downregulated in HCC tissues. Underexpression of DLC1 correlated with AFP level, vascular invasion, poor differentiation, and poor prognosis. In vitro assays revealed that DLC1 not only suppressed the proliferation, migration, and invasion of HCC cells, but also inhibited autophagy of HCC cells. Mechanistic investigation revealed that DLC1 decreased TCF4 expression and the interaction between beta-catenin and TCF4, then inactivated Wnt/beta-catenin signaling. Additionally, DLC1 suppressed the ROCK1 activity and the dissociation of the Beclin1-Bcl2 complex, thereby inhibiting autophagy of HCC cells. In conclusion, our findings imply that loss of DLC1 contributes to the progression and oncogenic autophagy of HCC.
引用
收藏
页码:1014 / 1024
页数:11
相关论文
共 50 条
[21]   Cancer-Associated Point Mutations in the DLC1 Tumor Suppressor and Other Rho-GAPs Occur Frequently and Are Associated with Decreased Function [J].
Wang, Dunrui ;
Qian, Xiaolan ;
Sanchez-Solana, Beatriz ;
Tripathi, Brajendra K. ;
Durkin, Marian E. ;
Lowy, Douglas R. .
CANCER RESEARCH, 2020, 80 (17) :3568-3579
[22]   Oncogenic role of phospholipase C-γ1 in progression of hepatocellular carcinoma [J].
Tang, Wenqing ;
Zhou, Yi ;
Sun, Dalong ;
Dong, Ling ;
Xia, Jinglin ;
Yang, Biwei .
HEPATOLOGY RESEARCH, 2019, 49 (05) :559-569
[23]   The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1 [J].
Sanchez-Solana, Beatriz ;
Wang, Dunrui ;
Qian, Xiaolan ;
Velayoudame, Parthibane ;
Simanshu, Dhirendra K. ;
Acharya, Jairaj K. ;
Lowy, Douglas R. .
MOLECULAR CANCER, 2021, 20 (01)
[24]   Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells [J].
Zhou, Xiaoling ;
Yang, Xu-Yu ;
Popescu, Nicholas C. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 420 (02) :325-330
[25]   Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer [J].
Chen, Zhaofeng ;
Liu, Xiaoguang ;
Hu, Zenan ;
Wang, Yuping ;
Liu, Min ;
Liu, Xiaojun ;
Li, Hailong ;
Ji, Rui ;
Guo, Qinhong ;
Zhou, Yongning .
ONCOLOGY LETTERS, 2015, 10 (01) :329-336
[26]   Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK) [J].
Li, Guorong ;
Du, Xiaoli ;
Vass, William C. ;
Papageorge, Alex G. ;
Lowy, Douglas R. ;
Qian, Xiaolan .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (41) :17129-17134
[27]   Novel oncogenes and tumor suppressor genes in Hepatocellular Carcinoma: Carcinogenesis, progression, and therapeutic targets [J].
Rahimi-Farsi, Nasim ;
Bostanian, Fatemeh ;
Shahbazi, Taha ;
Shamsinejad, Fatemeh Sadat ;
Bolideei, Mansoor ;
Mohseni, Parvin ;
Zangooie, Alireza ;
Boustani, Farnaz ;
Shoorei, Hamed .
GENE, 2025, 941
[28]   Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model [J].
Chen, Bo ;
Xu, Mingzheng ;
Xu, Ming .
ONCOLOGY LETTERS, 2019, 18 (05) :5600-5606
[29]   Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer [J].
Singh, Deepika ;
Bharti, Amisha ;
Biswas, Dipanjan ;
Tewari, Mallika ;
Kar, Amrita Ghosh ;
Ansari, Mumtaz Ahmed ;
Singh, Sunita ;
Narayan, Gopeshwar .
JOURNAL OF GASTROINTESTINAL CANCER, 2022, 53 (02) :237-244
[30]   Schisandrin B inhibits tumor progression of hepatocellular carcinoma by targeting the RhoA/ROCK1 pathway [J].
Yang, Hui ;
Wu, Tengfei .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (02) :533-543